These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36936866)

  • 1. Spesolimab use in treatment of pyoderma gangrenosum.
    Guénin SH; Khattri S; Lebwohl MG
    JAAD Case Rep; 2023 Apr; 34():18-22. PubMed ID: 36936866
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
    Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of pemphigus vegetans and exacerbation of pemphigus foliaceus after secukinumab loading in a patient with complicated generalized pustular psoriasis and pyoderma gangrenosum.
    Minai L; Takeichi T; Ogawa Y; Honobe-Tabuchi A; Okamoto T; Mitsui H; Shimada S; Akiyama M; Kawamura T
    J Dermatol; 2023 Feb; 50(2):245-249. PubMed ID: 36052669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.
    Pathak GN; Wang E; Dhillon J; Parikh PN; Esseghir R; Rao BK; Feldman SR
    Ann Pharmacother; 2024 May; ():10600280241252688. PubMed ID: 38755971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.
    Shao S; Wang G
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2627-2635. PubMed ID: 36208408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of Spesolimab for Generalized Pustular Psoriasis.
    Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
    N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
    Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
    BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterisation of Flare Treatment in EFFISAYIL® 1.
    Farag A; Visvanathan S; Bachelez H; Morita A; Lebwohl MG; Barker JN; Choon SE; Burden AD; Tsai TF; Leparc G; Delic D; Lang B; Thoma C; Krueger JG
    J Invest Dermatol; 2024 Jul; ():. PubMed ID: 39004117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.
    Navarini AA; Prinz JC; Morita A; Tsai TF; Viguier MA; Li L; Thoma C; Sivalingam M; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):730-736. PubMed ID: 36527385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report.
    Nazir A; Zafar A
    Cureus; 2022 May; 14(5):e25177. PubMed ID: 35746991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spesolimab: First Approval.
    Blair HA
    Drugs; 2022 Nov; 82(17):1681-1686. PubMed ID: 36418672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous occurrence of Pyoderma Gangrenosum and Palmoplantar Pustular Psoriasis: Is it an association or coincidental findings?
    Pukar C; Sudha A; Punam P
    Clin Case Rep; 2021 Jan; 9(1):410-415. PubMed ID: 33489191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified dose of guselkumab for treatment of pyoderma gangrenosum.
    Reese AM; Erickson K; Reed KB; Ortega-Loayza AG
    JAAD Case Rep; 2022 Mar; 21():38-42. PubMed ID: 35146098
    [No Abstract]   [Full Text] [Related]  

  • 17. Pure Bullous Pyoderma Gangrenosum, a Challenging Clinico-Pathological Diagnosis: Critical Literature Review with Emphasis on Diagnostic Criteria.
    García-Abellás P; Fernández-Guarino M; Díaz-Guimaraens B; Soto-Castillo JJ; Torres-Jiménez J; Carrillo-Gijón R
    Indian J Dermatol; 2022; 67(4):409-414. PubMed ID: 36578743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma Gangrenosum: An Ulcer With Unorthodox Treatment.
    Baruah TD; Ray R; R M
    Cureus; 2021 Nov; 13(11):e19324. PubMed ID: 34900493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathergic postsurgical-induced Pyoderma gangrenosum].
    Wirtzfeld N; Paquet P; Lemineur T; Lutgen M; Bouaziz JD; Denoel C
    Rev Med Liege; 2017 May; 72(5):227-232. PubMed ID: 28520320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report.
    Vallerand IA; Hardin J
    SAGE Open Med Case Rep; 2019; 7():2050313X19845206. PubMed ID: 31080598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.